Results of Annual General Meeting

Sydney, 17 November 2026: Clinical-stage biotech company **Noxopharm Limited (ASX:NOX)** is pleased to announce the results of today's Annual General Meeting.

The results are set out in the attached document, in accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act.

All resolution were passed and decided by way of poll. In respect to Resolution 1 "Adoption of Remuneration Report", the resolution passed with an excess of 75% voted in favour of the resolution.

-ENDS-

Investor, Corporate & Media enquiries:
Julian Elliott
M: 0425 840 071
E: julian.elliott@noxopharm.com

Gabriella Hold
The Capital Network
M: 0411 364 382
E: gaby@thecapitalnetwork.com.au

Company Secretary:
Shawn van Boheemen
T: +61 414 903 376
E: shawn.vanboheemen@noxopharm.com

About Noxopharm

Noxopharm Limited (ASX:NOX) is a clinical-stage Australian biotech company developing novel, targeted therapies for chronic inflammation, autoimmune diseases and cancer.

Noxopharm's proprietary Sofra™ platform is designed to regulate innate immune signalling with greater precision. Its lead clinical asset, SOF-SKN™, is a topical therapy initially being developed for cutaneous lupus erythematosus, with Phase I completed and further clinical development progressing.

Beyond SOF-SKN, the Sofra platform supports a broader pipeline of internal and externally collaborated programs across inflammatory and autoimmune diseases, RNA therapeutics and oncology.

To learn more, please visit: noxopharm.com

About the Sofra technology platform

Developed from a breakthrough discovery in innate immunology, the Sofra technology platform represents a revolutionary approach to drug design by translating a new understanding of innate biology into targeted therapeutics that enable precision control of disease-relevant signalling.

Sofra is based on the use of synthetic nucleic acids, known as oligonucleotides, to mimic natural regulators of the body's defence system.

This novel approach enables selective and modular tuning of immune sensors, reducing or stimulating their associated biological responses to mitigate a broad range of diseases and enhance RNA-based therapies and emerging therapeutic technologies.

Sofra is focused on inflammatory and autoimmune diseases such as rheumatoid arthritis, lupus and diabetes, as well as immuno-oncology for cancer treatment. The global autoimmune disease therapeutics market was worth US$163.2 billion in 2024 and is expected to reach US$219.6 billion by 2035, while the worldwide immuno-oncology market was US$43 billion in 2023 and is projected to hit US$284 billion by 2033.

Further information and animations: SOF-SKN / SOF-VAC

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.

Results of Meeting

Noxopharm Limited

Annual General Meeting

Tuesday, 17 November 2026

Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

		Proxy Votes (as at proxy voting close)				Poll Results (if applicable)			Results
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**
1 Adoption of Remuneration Report	P	51,233,529 99.00%	84,492 0.16%	69,600	432,510 0.84%	58,869,189 99.86%	84,492 0.14%	69,600	-
2 Re-election of Mr Frederick Bart as Director	P	52,172,939 99.09%	45,082 0.09%	1,958,762	432,510 0.82%	66,057,250 99.93%	45,082 0.07%	1,958,762	Carried
3 ASX Listing Rule 7.1A Approval of Future Issue of Securities	P	54,052,748 99.11%	54,435 0.10%	69,600	432,510 0.79%	67,937,059 99.92%	54,435 0.08%	69,600	Carried
4 Approval to Issue Shares to Fred Bart in Lieu of Accrued Directors' Fees	P	52,156,229 98.94%	124,192 0.24%	1,894,362	434,510 0.82%	60,423,889 99.79%	124,192 0.21%	7,513,013	Carried
5 Approval to Issue Shares to Snowy Plains Pty Ltd, an entity controlled by Boris Patkin in Lieu of Accrued Directors' Fees	P	54,024,709 98.96%	132,374 0.24%	17,700	434,510 0.80%	67,281,020 99.80%	132,374 0.20%	647,700	Carried
6 Approval to Issue Shares to Shanti Capital Pty Ltd an entity controlled by Peter Marks in Lieu of Accrued Directors' Fees	P	53,124,709 98.94%	132,374 0.25%	17,700	434,510 0.81%	67,011,020 99.80%	132,374 0.20%	17,700	Carried